08:00 , Nov 13, 2014 |  BC Innovations  |  Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Clinical News

AERAS-456: Phase I/IIa started

Not-for-profit Aeras and the Danish government institute said the South African Tuberculosis Vaccine Initiative (SATVI) began a 2-part, double-blind, South African Phase I/IIa trial to evaluate 3 doses of AERAS-456 containing 5, 15 or 50...